Nasdaq
華爾街日報- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock –
Read more at globenewswire.comAEON Biopharma Announces Execution of Exchange Agreement with Daewoong
Barchart·12/15/2025 15:05:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.